Search results
Showing 3316 to 3330 of 8933 results
This indicator covers the percentage of patients with diabetes, on the register, with a diagnosis of nephropathy (clinical proteinuria) or micro-albuminuria who are currently treated with an ACE-I (or ARBs). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM95.
This indicator covers the percentage of patients on the CKD register who are treated with an SGLT-2 inhibitor if they have: type 2 diabetes, or no type 2 diabetes and an eGFR 20 ml/min/1.73 m2 to 44 ml/min/1.73 m2 and are currently treated with an ACE inhibitor or angiotensin receptor blocker (ARB) (unless these are contraindicated) or an eGFR 45 ml/min/1.73 m2 to 59 ml/min/1.73 m2, are currently treated with an ACE inhibitor or ARB (unless these are contraindicated) and have a urine albumin-to-creatinine ratio (ACR) of 22.6 mg/mmol or more. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes.
The complete list of all our published indicators, for measuring outcomes that reflect the quality of care or processes, linked by evidence to improved outcomes.
Early value assessment (EVA) guidance on artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway.
NICE work with the NHS, patients and carers, healthcare professionals and organisations to help put our guidance into practice.
Find out what guidance is being considered for development
Agenda and papers of the NICE public board meeting on 18 March 2026
Home About us Our board Public board meetings 2026 {"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem"
Home Get involved Our committees...
How to register with us as a diagnostic technologies stakeholder.
Stakeholder registration: guidelines, quality standards and indicators
How to register as a stakeholder to help us develop guidelines, quality standards and indicators.
GPs help to bring a primary care perspective to the guidance that we produce.
Read NICE's patient and public involvement policy.
How to register with us as a medical technologies stakeholder.
People can comment on our guidance at specific stages in its development.